var data={"title":"Canagliflozin and metformin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Canagliflozin and metformin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/749150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=canagliflozin-and-metformin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Canagliflozin and metformin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28194345\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Canagliflozin Safety Alert</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">Based on new data from 2 large clinical trials, the FDA and Health Canada have concluded that canagliflozin causes an increased risk of leg and foot amputations. The canagliflozin drug labeling will be updated to describe this risk.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Before initiating canagliflozin therapy, health care providers should consider factors that may predispose patients to the need for amputations; these factors include a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Providers should monitor patients receiving canagliflozin for the signs and symptoms described above and should discontinue canagliflozin if these complications occur. Patients taking canagliflozin should notify their providers immediately if they develop new pain or tenderness, sores or ulcers, or infections in their legs or feet. Patients should not stop taking their diabetes medicine without first consulting their provider.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at https://www.fda.gov/downloads/Drugs/DrugSafety/UCM558427.pdf and http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/64366a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573727\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate:pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), age 65 years or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (eg, acute heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information. If metformin-associated lactic acidosis is suspected, immediately discontinue canagliflozin/metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lower limb amputation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">An approximately 2-fold increased risk of lower limb amputations associated with canagliflozin use was observed in CANVAS and CANVAS-R, 2 large, randomized, placebo-controlled trials in patients with type 2 diabetes who had established cardiovascular disease (CVD) or were at risk for CVD. Amputations of the toe and midfoot were most frequent; however, amputations involving the leg were also observed. Some patients had multiple amputations, some involving both limbs. Before initiating, consider factors that may increase the risk of amputation, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Monitor patients receiving canagliflozin for infection, new pain or tenderness, sores or ulcers involving the lower limbs, and discontinue if these complications occur.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25593249\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Invokamet;</li>\n      <li>Invokamet XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48874516\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Invokamet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573728\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Biguanide;</li>\n      <li>\n        Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor;</li>\n      <li>\n        Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746086\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If present, correct volume depletion prior to initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: Individualize dose based on patient's current antidiabetic regimen. May gradually increase dose based on effectiveness and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients na&iuml;ve to canagliflozin or metformin</i>: Initial: Canagliflozin 100 mg/metformin 1,000 mg per day in 2 divided doses (immediate release) or once daily (ER).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients on metformin</i>: Initial: Canagliflozin 100 mg/day plus similar total daily dose of metformin in 2 divided doses (immediate release) or once daily (ER). Patients taking an evening dose of metformin ER should skip their last dose before starting canagliflozin/metformin ER the following morning.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients on canagliflozin</i>: Initial: Metformin 1,000 mg/day plus same total daily dose of canagliflozin in 2 divided doses (immediate release) or once daily (ER).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients switching from combination therapy of canagliflozin and metformin as separate tablets:</i> Administer same total daily dose of canagliflozin plus similar total daily dose of metformin in 2 divided doses (immediate release) or once daily (ER).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients switching from immediate release to ER</i>: Use current total daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum: Canagliflozin 300 mg/metformin 2,000 mg per day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment for concomitant therapy with UDP-glucuronosyl transferase (UGT) inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir):</b> Consider increasing the dose of canagliflozin/metformin to canagliflozin 300 mg/day in patients currently tolerating canagliflozin 100 mg/day who have eGFR &ge;60 mL/minute/1.73 m<sup>2</sup> and require additional glycemic control. If patient is receiving concurrent UGT enzyme inducers <b>and</b> has eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>, consider alternate therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746087\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746088\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>:  Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving concurrent UGT enzyme inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir) and has eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>, consider the use of another antidiabetic agent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &lt;45 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End stage renal disease (ESRD) or hemodialysis: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746089\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer recommends avoiding metformin because liver disease is considered a risk factor for the development of lactic acidosis during metformin therapy. However, continued use of metformin in patients with diabetes with liver dysfunction, including cirrhosis, has been used successfully and may be associated with a survival benefit in carefully selected patients; use cautiously in patients at risk for lactic acidosis (eg, renal impairment, alcohol use) (Brackett 2010; Zhang 2014). For canagliflozin, no dosage adjustment is necessary in patients with mild or moderate hepatic impairment according to the manufacturer's labeling; use of canagliflozin is not recommended in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25593250\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invokamet: Canagliflozin 50 mg and metformin hydrochloride 500 mg, Canagliflozin 150 mg and metformin hydrochloride 500 mg, Canagliflozin 50 mg and metformin hydrochloride 1000 mg, Canagliflozin 150 mg and metformin hydrochloride 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invokamet XR: Canagliflozin 50 mg and metformin hydrochloride 500 mg, Canagliflozin 150 mg and metformin hydrochloride 500 mg, Canagliflozin 50 mg and metformin hydrochloride 1000 mg, Canagliflozin 150 mg and metformin hydrochloride 1000 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25593248\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50539649\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the United States. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invokamet: Canagliflozin 50 mg and metformin hydrochloride 850 mg; Canagliflozin 150 mg and metformin hydrochloride 850 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746070\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invokamet: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204353s023lbl.pdf#page=52&amp;token=cD5BqvxrtHdqqaZIe91LBORBQlmGyRprDD2efYjhhc9H84NbLxLHVXT0V01OZ9ZcHQUIyNup1/JU5U2NTcR/IKHBId3KbTt97udhln4lv1QPu/3vbOqTgmT9GYrEqncX&amp;TOPIC_ID=96545\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204353s023lbl.pdf#page=52</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invokamet XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205879s005lbl.pdf#page=52&amp;token=ZtNyaDfKx5GnQZYESh+9zUrFI+R8gop5wqgYUEvxjNpH84NbLxLHVXT0V01OZ9ZcxNebYj8Y1Ik4TKFBh1MzhMNFYDd1CKUQu8/ncLJk+5D3wM0ipP0TeICZImLcYO5H&amp;TOPIC_ID=96545\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205879s005lbl.pdf#page=52</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746092\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Administer twice daily with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Administer once daily with morning meal. Swallow tablets whole; do not crush, cut, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573725\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25707879\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetFORMIN may be confused with metroNIDAZOLE</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25872220\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573730\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">History of serious hypersensitivity (eg, anaphylaxis, angioedema) to canagliflozin, metformin, or any component of the formulation; moderate to severe renal impairment (eGFR &lt;45 mL/minute/1.73 m<sup>2</sup>); end-stage renal disease (ESRD) or patients on dialysis; acute or chronic metabolic acidosis (including diabetic ketoacidosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Renal function unknown, serum creatinine levels above the upper limit of normal range, or renal dysfunction (serum creatinine &ge;136 micromol/L in males or &ge;124 micromol/L in females or abnormal creatinine clearance &lt;60 mL/minute) which may result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia; unstable and/or insulin-dependent (type I) diabetes mellitus; acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma; history of lactic acidosis (regardless of precipitating factors); excessive alcohol intake (acute or chronic); severe hepatic dysfunction or clinical or laboratory evidence of hepatic disease; cardiovascular collapse and disease states associated with hypoxemia including cardiorespiratory insufficiency, which are often associated with hyperlactacidemia; stress conditions (eg, severe infection, trauma, surgery and postoperative recovery phase); severe dehydration; pregnancy; breast-feeding; period of time around administration of iodinated contrast materials</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746079\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fracture: An increased incidence of bone fractures has been observed in some clinical trials and may occur as early as 12 weeks after treatment initiation. Consider patient's risk of fracture prior to initiation. Meta-analyses of trial data for canagliflozin, dapagliflozin, and empagliflozin have not demonstrated increased risk of fracture overall (Ruanpeng 2017; Tang 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Genital mycotic infections: Canagliflozin may increase the risk of genital mycotic infections (eg, vulvovaginal mycotic infection, vulvovaginal candidiasis, vulvovaginitis, candida balanitis, balanoposthitis). Patients with a history of these infections or uncircumcised males are at greater risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Canagliflozin may cause hyperkalemia. Patients predisposed to hyperkalemia (including patients with renal impairment or taking potassium-sparing diuretics, ACE inhibitors, and ARBs) are more likely to develop hyperkalemia; monitor serum potassium after initiation in those who are predisposed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (eg, angioedema, anaphylaxis), some serious, generally occurs within hours to days after therapy initiation. Discontinue therapy if hypersensitivity occurs and treat as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Canagliflozin may cause symptomatic hypotension due to intravascular volume depletion especially in patients with renal impairment (ie, eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>), elderly, patients on other antihypertensives (eg, diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]), or those with low systolic blood pressure. Assess volume status prior to initiation in patients at risk of hypotension and correct if depleted; monitor for signs and symptoms of hypotension after initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ketoacidosis: Cases of ketoacidosis (some fatal) have been reported in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose cotransporter-2 (SGLT2) inhibitors; in some cases, patients have presented with normal or only modestly elevated blood glucose (&lt;250 mg/dL) (Bobart 2016; FDA 2015; Handelsman 2016). Before initiating treatment, consider risk factors that may predispose to ketoacidosis (eg, pancreatic insulin deficiency, dose decreases or discontinuation of insulin, caloric restriction, alcohol abuse, extensive exercise, MI, stroke, severe infection, surgery, any other extreme stress event) (Handlelsman 2016). The American Association of Clinical Endocrinologists and American College of Endocrinology recommend considering withholding of SGLT2 inhibitors for at least 24 hours prior to events that may precipitate diabetic ketoacidosis (Handelsman 2016), while others have suggested withholding for 3 to 5 days (Bobart 2016). Patients presenting with nausea/vomiting, abdominal pain, generalized malaise, and/or shortness of breath should be assessed immediately for ketoacidosis; discontinue therapy and treat promptly if ketoacidosis is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis: <b>[US Boxed Warning]: Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset is often subtle, accompanied by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain); elevated blood lactate levels (&gt;5 mmol/L); anion gap acidosis (without evidence of ketonuria or ketonemia); increased lactate:pyruvate ratio; metformin plasma levels generally &gt;5 mcg/mL. Risk factors for lactic acidosis include patients with renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), &ge;65 years, having a radiologic study with contrast, surgery and other procedures, hypoxic states (eg, acute heart failure), excessive alcohol intake, and hepatic impairment. Discontinue immediately if lactic acidosis is suspected; prompt hemodialysis is recommended.</b> Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue use in patients with conditions associated with dehydration, hypoperfusion, sepsis, or hypoxemia. Temporarily discontinue therapy in patients with restricted food and fluid intake. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipid abnormality: Canagliflozin may cause dose-related LDL-cholesterol (C) elevation; monitor LDL-C and treat as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower limb amputation: <b>[US Boxed Warning]: An approximately 2-fold increased risk of lower limb amputations associated with canagliflozin use was observed in 2 large, randomized, placebo-controlled trials evaluating patients with type 2 diabetes who had either established cardiovascular disease or were at risk for cardiovascular disease. Amputations involved the toe, midfoot, or less frequently the leg (above or below the knee). Lower limb infections, gangrene, and diabetic foot ulcers were the most common precipitating factors. Prior to initiation consider risk factors for amputation including prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Counsel patients about the importance of preventative foot care. Discontinue therapy if any of the following occur: signs and symptoms of new infection (including osteomyelitis), new pain or tenderness, or sores/ulcers involving the lower limbs.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Acute kidney injury has been reported with canagliflozin. Prior to initiation, consider risk factors for acute kidney injury (eg, hypovolemia, chronic renal insufficiency, heart failure, use of concomitant medications [eg, diuretics, ACE inhibitors, angiotensin receptor blockers, or NSAIDs]). Temporarily discontinue use with reduced oral intake or fluid losses; discontinue use if acute kidney injury occurs. Additional abnormalities in renal function (decreased eGFR, increased serum creatinine) and adverse effects related to renal function may occur. Assess renal function prior to initiation and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract infection: Serious urinary infections including urosepsis and pyelonephritis requiring hospitalization have been reported with canagliflozin; treatment increases the risk for urinary tract infections (UTI); monitor for signs and symptoms of UTI and treat as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> concentrations: Long-term metformin use is associated with vitamin B<sub>12</sub> deficiency; monitor vitamin B<sub>12</sub> serum concentrations periodically with long-term therapy. Monitoring of B<sub>12</sub> serum concentrations should be considered in all patients receiving metformin and in particular those with peripheral neuropathy or anemia (ADA 2018c).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Metformin may be used in patients with stable heart failure (HF); avoid use in unstable or hospitalized patients with heart failure (ADA 2018e). Risk of lactic acidosis may be increased secondary to hypoperfusion. In a scientific statement from the AHA, metformin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]). Use of metformin in patients with HF may be associated with reduced mortality and reduction in hospital readmission for HF (Crowley 2017; Eurich 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver dysfunction, including cirrhosis, may be associated with a survival benefit in carefully selected patients (Brackett 2010; Crowley 2017; Zhang 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metformin accumulation and lactic acidosis increase with degree of renal impairment. Dosage adjustment recommended if eGFR &lt;60 mL/minute/1.73m<sup>2</sup>; use of combination product is contraindicated in patients with an eGFR &lt;45 mL/minute/1.73 m<sup>2</sup>, end stage renal disease, or maintained on dialysis. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia. Glycemic efficacy of canagliflozin may be decreased in renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; risk of metformin associated lactic acidosis increases with age. Elderly patients (&ge;65 years) may have an increased risk of symptoms related to intravascular volume depletion (eg, hypotension, orthostatic hypotension, postural dizziness, syncope, and dehydration) during canagliflozin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not for use in patients with diabetic ketoacidosis (DKA) <b>or</b> patients with type 1 diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 45 to 60 mL/minute/1.73 m<sup>2</sup>; or with a history of hepatic disease, alcoholism, or heart failure; or in patients who will receive intra-arterial iodinated contrast. Reevaluate eGFR 48 hours after imaging procedure; restart if renal function is stable. Alternatively, the American College of Radiology (ACR) guidelines recommend that metformin may be used prior to or following administration of iodinated contrast media in patients with no evidence of acute kidney injury (AKI) and with an eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>; ACR guidelines recommend temporary discontinuation of metformin in patients with known AKI or severe chronic kidney disease ([stage IV or V [ie, eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>]) or who are undergoing arterial catheter studies (ACR 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical procedures: Metformin should be withheld the day of surgery (all other oral hypoglycemic agents should be withheld the morning of surgery or procedure) (ADA 2018d).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25590551\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25590548\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=96545&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of MetFORMIN. Specifically, alcohol may potentiate the risk of lactic acidosis<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Canagliflozin may enhance the hyperkalemic effect of Aliskiren. Canagliflozin may enhance the hypotensive effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Canagliflozin may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Canagliflozin may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dalfampridine: MetFORMIN may increase the serum concentration of Dalfampridine. Dalfampridine may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: May increase the serum concentration of MetFORMIN. Management: Limit the daily metformin dose to 1,000 mg when used together with dolutegravir.  Metformin dose adjustments may also be needed upon discontinuation of dolutegravir.  Monitor patient response to metformin closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Canagliflozin may enhance the hyperkalemic effect of Eplerenone. Canagliflozin may enhance the hypotensive effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Canagliflozin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Canagliflozin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors may enhance the hypoglycemic effect of Insulins.  Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Management advice varies. Refer to the full drug interaction monograph content for details.<b> Exceptions: </b>Diatrizoate Meglumine; Diatrizoate Sodium; Ethiodized Oil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Canagliflozin may enhance the hypotensive effect of Loop Diuretics.  Management: If canagliflozin is combined with a loop diuretic, monitor for symptoms of intravascular volume depletion and hypotension. Canadian product labeling recommends avoiding the combination of canagliflozin and loop diuretics.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ondansetron: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patiromer: May decrease the serum concentration of MetFORMIN. Management: Administer metformin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Canagliflozin may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of MetFORMIN. Management: Limit the metformin dose to a maximum of 1700 mg/day when used together with ranolazine 1000 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May enhance the adverse/toxic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trospium: MetFORMIN may decrease the serum concentration of Trospium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vandetanib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May diminish the therapeutic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746076\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Metformin crosses the placenta (ADA 2018f). The manufacturer recommends that alternative therapies be used in pregnant women, especially during the second and third trimesters. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746078\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low amounts of metformin are excreted into breast milk (Briggs 2005; Eyal 2010; Gardiner 2003; Hale 2002); excretion of canagliflozin is not known. Due to the potential for serious adverse reactions in the nursing infant, breastfeeding is not recommended by the manufacturer. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746091\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be taken with meals. Avoid ethanol. Dietary modification based on ADA recommendations is a part of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746094\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin A<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]); plasma glucose, hematologic parameters (eg, hemoglobin/hematocrit and red blood cell indices); renal function (baseline then annually or when clinically indicated); volume status (eg blood pressure, hematocrit, electrolytes); hematologic parameters (annually); vitamin B<sub>12</sub> (periodically with long-term treatment) and folate (if megaloblastic anemia is suspected); blood pressure; LDL-C; serum potassium; signs and symptoms of genital mycotic infections and UTI; signs and symptoms of metabolic acidosis; lower limb and feet (sores, ulcers, infection).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746083\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746081\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Canagliflozin: By inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, canagliflozin reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RTG). SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RTG result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Metformin: Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25746084\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25745808\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Invokamet XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-500 mg (60): $557.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-1000 mg (60): $557.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150-500 mg (60): $557.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150-1000 mg (60): $557.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Invokamet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-500 mg (60): $557.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-1000 mg (60): $557.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150-500 mg (60): $557.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150-1000 mg (60): $557.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25576794\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vokanamet (AT, CY, CZ, DE, DK, EE, ES, FI, FR, GB, HR, IE, LT, LU, MT, NL, PL, PT, RO, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.3. https://www.acr.org/Clinical-Resources/Contrast-Manual. Published 2017. Accessed January 3, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 4. Lifestyle management: standards of medical care in diabetes-2018.<i> Diabetes Care.</i> 2018c;41(Suppl 1):S38-S50. doi:10.2337/dc18-S004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29222375/pubmed\" target=\"_blank\" id=\"29222375\">29222375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 14. Diabetes care in the hospital: standards of medical care in diabetes-2018. <i>Diabetes Care.</i> 2018d;41(suppl 1):S144-S151. doi: 10.2337/dc18-S014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29222385/pubmed\" target=\"_blank\" id=\"29222385\">29222385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018e;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29222380/pubmed\" target=\"_blank\" id=\"29222380\">29222380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018f;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: a case report. <i>Ann Intern Med</i>. 2016;165(7):530-532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27699391/pubmed\" target=\"_blank\" id=\"27699391\">27699391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC. Clarifying metformin&rsquo;s role and risks in liver dysfunction. <i>J Am Pharm Assoc (2003)</i>. 2010;50(3):407-410.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/20452916/pubmed\" target=\"_blank\" id=\"20452916\">20452916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briggs GG, Ambrose PJ, Nageotte MP, et al. Excretion of metformin into breast milk and the effect on nursing infants. <i>Obstet Gynecol</i>. 2005;105:1437-1441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/15932841/pubmed\" target=\"_blank\" id=\"15932841\">15932841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. <i>Ann Intern Med</i>. 2017;166(3):191-200. doi: 10.7326/M16-1901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/28055049/pubmed\" target=\"_blank\" id=\"28055049\">28055049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. <i>Circ Heart Fail</i>. 2013;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/23508758/pubmed\" target=\"_blank\" id=\"23508758\">23508758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. <i>Drug Metab Dispos</i>. 2010;38:833-840.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/20118196/pubmed\" target=\"_blank\" id=\"20118196\">20118196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Food and Drug Administration website. <a href=\"http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm</a>. Published December 4, 2015. Accessed October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of metformin into human milk. <i>Clin Pharmacol Ther</i>. 2003;73:71-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/12545145/pubmed\" target=\"_blank\" id=\"12545145\">12545145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin into human milk. <i>Diabetologia</i>. 2002;45:1509-1514.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/12436333/pubmed\" target=\"_blank\" id=\"12436333\">12436333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. <i>Endocr Pract</i>. 2016;22(6):753-762.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27082665/pubmed\" target=\"_blank\" id=\"27082665\">27082665</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invokamet (canagliflozin and metformin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invokamet (canagliflozin and metformin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invokamet XR (canagliflozin and metformin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invokana (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular and Stroke Nursing, Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. <i>Diabetes Metab Res Rev</i>. 2017;33(6). doi: 10.1002/dmrr.2903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/28440590/pubmed\" target=\"_blank\" id=\"28440590\">28440590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2016;18(12):1199-1206. doi: 10.1111/dom.12742.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/27407013/pubmed\" target=\"_blank\" id=\"27407013\">27407013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i>. 2014;60(6):2008-2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canagliflozin-and-metformin-drug-information/abstract-text/24798175/pubmed\" target=\"_blank\" id=\"24798175\">24798175</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 96545 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F28194345\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F25573727\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F25593249\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F48874516\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F25573728\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F25746086\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F25746087\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25746088\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25746089\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F25593250\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F25593248\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50539649\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25746070\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25746092\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25573725\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25707879\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F25872220\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25573730\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F25746079\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F25590551\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F25590548\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F25746076\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F25746078\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F25746091\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25746094\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F25746083\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F25746081\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F25746084\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F25745808\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25576794\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/96545|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=canagliflozin-and-metformin-patient-drug-information\" class=\"drug drug_patient\">Canagliflozin and metformin: Patient drug information</a></li></ul></div></div>","javascript":null}